Review of Gaps in the Clinical Indications and Use of Neural Conduits and Artificial Grafts for Nerve Repair and Reconstruction
Chan YM., Judge NG., Hu Y., Willits RK., Li N., Becker ML.
Narrative Review, published in Biomacromolecules (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Biomacromolecules (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40562739
- PMCID
- PMC13107395
- DOI
- 10.1021/acs.biomac.5c00558
- Citations
- 8
Abstract (original English)
Peripheral nerve injuries remain a significant clinical challenge, with limited tools available to physicians and patients. Although autografts are the gold standard for nerve reconstruction, they are limited by donor-site morbidity and availability. Commercially available nerve guidance conduits offer alternatives, yet their clinical application remains largely restricted to short nerve gaps with limited success beyond 1 cm. This review provides a summary of the clinical studies on nerve injury repair using commercial nerve guidance conduits and discusses the shortcomings of such devices, including suboptimal mechanical properties, lack of internal guidance structures and bioactivity, and insufficient clinical data. To address these challenges, emerging innovations, such as biofunctionalized materials, conductive scaffolds, and topographically engineered architectures, are readily being explored to improve regenerative outcomes following neural injury. Overall, this work highlights the gaps in commercial devices utilized clinically and brings attention to the evolving landscape of biomaterials research that can transform clinical nerve repair.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.